- Report
- June 2021
- 77 Pages
Global
From €4691EUR$4,950USD£3,959GBP
- Report
- January 2020
- 39 Pages
Global
From €900EUR$950USD£760GBP
- Report
- February 2024
- 209 Pages
Global
From €4596EUR$4,850USD£3,879GBP
- Report
- October 2023
- 85 Pages
United States
From €4596EUR$4,850USD£3,879GBP
- Report
- March 2024
- 138 Pages
Global
From €2842EUR$2,999USD£2,398GBP
- Report
- March 2024
- 135 Pages
Global
From €2842EUR$2,999USD£2,398GBP
From €3317EUR$3,500USD£2,799GBP
- Report
- January 2025
- 85 Pages
Saudi Arabia
From €3317EUR$3,500USD£2,799GBP
- Report
- January 2025
- 85 Pages
Saudi Arabia
From €3317EUR$3,500USD£2,799GBP
From €3317EUR$3,500USD£2,799GBP
- Report
- September 2024
- 82 Pages
Japan
From €3317EUR$3,500USD£2,799GBP
- Report
- September 2024
- 80 Pages
France
From €3317EUR$3,500USD£2,799GBP
- Report
- August 2024
- 80 Pages
Japan
From €3317EUR$3,500USD£2,799GBP
- Report
- April 2024
- 88 Pages
France
From €3317EUR$3,500USD£2,799GBP
- Report
- February 2024
- 187 Pages
Global
From €4264EUR$4,500USD£3,599GBP
- Report
- February 2024
- 184 Pages
Global
From €4264EUR$4,500USD£3,599GBP
- Report
- February 2024
- 172 Pages
Global
From €4264EUR$4,500USD£3,599GBP
- Report
- November 2023
- 190 Pages
Global
From €4264EUR$4,500USD£3,599GBP
- Report
- October 2023
- 177 Pages
Global
From €4264EUR$4,500USD£3,599GBP
- Report
- October 2023
- 183 Pages
Global
From €4264EUR$4,500USD£3,599GBP

The Targeted Therapies market within the context of Genomics is focused on the development of treatments that target specific genetic mutations or pathways. These therapies are designed to be more effective and have fewer side effects than traditional treatments. Genomics has enabled the development of personalized treatments that are tailored to the individual patient's genetic makeup. This has allowed for the development of drugs that target specific mutations or pathways, leading to more effective treatments.
The Targeted Therapies market is a rapidly growing field, with many companies investing in research and development. Companies such as Gilead Sciences, Novartis, and AstraZeneca are leading the way in the development of targeted therapies. Other companies such as Merck, Pfizer, and Roche are also investing in the development of targeted therapies. Show Less Read more